Khashayar Sakhaee
UTSW · UT Southwestern
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Khashayar Sakhaee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:54 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05998863 · EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI TherapyUniversity of Texas Southwestern Medical Center · withdrawn · Osteoporosis, Hypomagnesemia · principal investigator
- Ph4NCT04370093 · Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight LossUniversity of Texas Southwestern Medical Center · completed · Nephrolithiasis, Uric Acid · principal investigator
- Ph3NCT03812380 · Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium CitrateUniversity of Texas Southwestern Medical Center · terminated · Osteoporosis, Hypomagnesemia · principal investigator
- N/ANCT02975986 · Renal Uptake of Fatty Acids (FFA) in Patients With Idiopathic Uric Acid Nephrolithiasis (IUAN)University of Texas Southwestern Medical Center · withdrawn · Uric Acid Nephrolithiasis · principal investigator
- N/ANCT00904046 · Pathophysiology of Uric Acid NephrolithiasisUniversity of Texas Southwestern Medical Center · completed · Uric Acid Kidney Stone Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Origin of Excess Acid in Uric Acid UrolithiasisR01DK115703 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2019 to 2023 · $449,722 awarded in 2023Same name and institution; not confirmed by an ID
- Pathogenesis of Uric Acid NephrolithiasisR01DK081423 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2009 to 2023 · $502,962 awarded in 2023Grant number is on one of their registry trials
- PATHOPHYSIOLOGY OF IDIOPATHIC URIC ACID NEPHROLITHIASISP01DK020543 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 1996 to 2008 · $182,924 awarded in 2008Same name and institution; not confirmed by an ID
- EFFECT OF POTASSIUM ALKALI ON BONE LOSS AND STONE RISK INDUCED BY ATKINS' DIETM01RR000633 · NCRR · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 1995 to 2007 · $13,257 awarded in 2007Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:54 UTC. The ranking covers the 200 most relevant of 32 PubMed records, and a shared surname and initials can bring in a namesake. All 32 on PubMed
- Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts.Kidney Int · 1983204 citationsRCR 8.6
- 190 citationsRCR 9.2
- Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial.Ann Intern Med · 1995181 citationsRCR 7.2
- Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis.J Am Soc Nephrol · 2006171 citationsRCR 5.2
- 146 citationsRCR 6.8
- Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures.J Clin Endocrinol Metab · 1989142 citationsRCR 7.6
- 142 citationsRCR 6.5
- Metabolic basis for low urine pH in type 2 diabetes.Clin J Am Soc Nephrol · 2010122 citationsRCR 4.1
- Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial.Ann Intern Med · 199489 citationsRCR 3.8
- Biochemical and stone-risk profiles with topiramate treatment.Am J Kidney Dis · 200686 citationsRCR 2.7